Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $71.06, for a total value of $390,830.00. Following the completion of the sale, the insider owned 209,773 shares of the company’s stock, valued at $14,906,469.38. The trade was a 2.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, February 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $65.79, for a total transaction of $361,845.00.
• On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The shares were sold at an average price of $77.84, for a total transaction of $1,455,608.00.

Apogee Therapeutics Stock Performance

NASDAQ APGE opened at $73.05 on Friday. The firm’s 50 day moving average price is $72.38 and its 200-day moving average price is $60.66. Apogee Therapeutics Inc. has a 52-week low of $26.20 and a 52-week high of $84.56. The company has a market cap of $5.08 billion, a PE ratio of -17.31 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.02. On average, analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apogee Therapeutics

Several institutional investors have recently added to or reduced their stakes in APGE. Commonwealth Equity Services LLC increased its holdings in shares of Apogee Therapeutics by 2.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock valued at $540,000 after acquiring an additional 152 shares in the last quarter. Stifel Financial Corp increased its stake in Apogee Therapeutics by 3.5% during the 4th quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock valued at $394,000 after purchasing an additional 175 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares in the last quarter. Comerica Bank raised its holdings in shares of Apogee Therapeutics by 1.0% in the fourth quarter. Comerica Bank now owns 35,872 shares of the company’s stock worth $2,708,000 after buying an additional 338 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after buying an additional 383 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Wall Street Analysts Forecast Growth

APGE has been the subject of a number of analyst reports. BTIG Research set a $137.00 price objective on Apogee Therapeutics in a research note on Tuesday, January 6th. Stifel Nicolaus set a $133.00 target price on shares of Apogee Therapeutics in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft began coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 9th. They set a “buy” rating and a $103.00 price target for the company. Wall Street Zen lowered shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Finally, Wedbush increased their target price on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.92.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.